All In Biotech

Drug Trial Radar · NCT06280235

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

A Phase II, 6-week, Multicenter, Randomized, Double Blind (Patient and Investigator) or Masked, Placebo Controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 as Adjunctive Therapy in MD

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 243 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

243

Actual

Start

Mar 27, 2024

Primary completion

Feb 26, 2025

Study completion Mar 28, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their standard therapy throughout the study. Participants are put into 4 groups by chance. 3 of the 4 groups take different doses of BI 1569912. 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks. Participants are in the study for about 2 to 4 and a half months. During this time, they visit the study site at least 6 times. At the visits, doctors ask participants about their symptoms. The participants answer questions about their depression symptoms. The results are compared between the groups. The doctors also regularly check the general health of participants.

Conditions

  • Depressive Disorder, Major

Interventions

  • BI 1569912Drug

    Tablets

  • PlaceboDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in MADRS Total Score at Week 6Time frame: MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.

Locations

52 sites in 7 countries. Site status is shown where the registry gives one.

  • Southwest Biomedical Research, LLC

    Tucson, Arizona

  • Excell Research Inc.

    Oceanside, California

  • NRC Research Institute

    Orange, California

  • Asclepes Research Centers-Panorama City-62905

    Panorama City, California

  • CT Clinical Research

    Cromwell, Connecticut

  • Galiz Research

    Hialeah, Florida

  • Premier Clinical Research Institute

    Miami, Florida

  • CCM Clinical Research Group, LLC-Miami-68482

    Miami, Florida

  • iResearch Atlanta

    Decatur, Georgia

  • Chicago Research Center, Incorporated

    Chicago, Illinois

  • ActivMed Practices & Research

    Methuen, Massachusetts

  • Boston Clinical Trials

    Roslindale, Massachusetts

  • Adams Clinical

    Watertown, Massachusetts

  • Hassman Research Institute-Marlton-66897

    Marlton, New Jersey

  • Neurobehavioral Research, Inc.

    Cedarhurst, New York

  • Midwest Clinical Research

    Dayton, Ohio

  • Neuro-Behavioral Clinical Research

    North Canton, Ohio

  • Sooner Clinical Research

    Oklahoma City, Oklahoma

  • Houston Clinical Trials, LLC

    Bellaire, Texas

  • Grayline Research Center

    Wichita Falls, Texas

  • Northwest Clinical Research Center

    Bellevue, Washington

  • Anima Research Center

    Alken, Belgium

  • Universitair Psychiatrisch Centrum Duffel (UPC Duffel)

    Duffel, Belgium

  • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry - Dr Ivo Natsov

    Cherven Bryag, Bulgaria

  • MHC - Ruse, EOOD

    Rousse, Bulgaria

  • Medical Center "Sv.Naum"

    Sofia, Bulgaria

  • DCC "Sv. Vrach and Sv. Sv. Kuzma and Damyan" OOD

    Sofia, Bulgaria

  • Medical Center Hera EOOD

    Sofia, Bulgaria

  • Medical Center Intermedica Ltd.

    Sofia, Bulgaria

  • DCC Mladost-M Varna OOD

    Varna, Bulgaria

  • Hebei Mental Health Center

    Baoding, China

  • Beijing Anding Hospital

    Beijing, China

  • Peking University Sixth Hospital

    Beijing, China

  • The Second Xiangya Hospital Of Central South University

    Changsha, China

  • Shanghai Mental Health Center

    Shanghai, China

  • Shenzhen Kangning Hospital

    Shenzhen, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, China

  • Tianjin Anding Hospital

    Tianjin, China

  • A-SHINE s.r.o

    Pilsen, Czechia

  • Clintrial s.r.o.

    Prague, Czechia

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.